Quantcast

Latest Actavis Stories

2014-04-03 08:31:17

Fuld & Company White Paper Released CAMBRIDGE, Mass., April 3, 2014 /PRNewswire/ -- A Fuld & Company white paper which chronicles the history of Forest Laboratories and its market position that led to its acquisition by Actavis was released today. The white paper http://bit.ly/1lAw5Lo provides details including: -- Forest's actions in recent years that made it acquisition bait -- How one of the most successful US pharmaceutical companies of the last decade finds itself...

2014-04-02 20:22:35

- Centralized Headquarters to help drive Company's Geographic Expansion, Growth in Emerging Markets throughout Southeast Asia - SINGAPORE, April 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced the official opening of its new regional office in Singapore that will serve as the headquarters for the Company's Asia Pacific and Africa (APACA) region. In addition, Actavis announced that its subsidiary operating in...

2014-04-01 08:29:34

- Establishes Leading Position in Fast-Growing Thai Pharmaceutical Market - DUBLIN, April 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. The acquisition of Silom Medical immediately elevates Actavis into a top-five position...

2014-04-01 08:28:47

DUBLIN, April 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has successfully completed the divestiture of its generics commercial operations in seven markets in Western Europe to Aurobindo Pharma Limited (BSE: 524804). The agreement to divest the commercial operations was announced in January 2014. http://photos.prnewswire.com/prnvar/20130124/NY47381LOGO Aurobindo acquired Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain,...

2014-03-28 16:22:54

DUBLIN, March 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda(®) (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). The Appeals Court found that the U.S. District Court for the Southern District of Florida did not correctly construe the claims of the '720 Patent, and...

2014-03-25 16:26:26

DUBLIN and LAVAL, Quebec, March 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Bacterial vaginosis...

2014-03-21 16:23:25

DUBLIN, March 21, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2014 financial results on Wednesday, April 30, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, April 30, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is...

2014-03-19 16:23:48

DUBLIN, March 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana(® )(Methylphenidate Transdermal System). Daytrana(®) is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. Under the terms of the agreement, Noven will grant Actavis a non-exclusive, royalty-bearing...

2014-03-12 20:24:16

DUBLIN, March 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid. Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for infringement of the '048 Patent in connection with its Abbreviated New Drug Application directed to Actavis' generic version of Pfizer's Celebrex® (celecoxib)...

2014-03-07 08:25:14

BOSTON, March 7, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related